Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Is smoking heaviness causally associated with alcohol use? A Mendelian randomization study in four European cohorts

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Parental socioeconomic status and risk of cerebral palsy in the child: evidence from two Nordic population-based cohorts

    Research output: Contribution to journalJournal articleResearchpeer-review

  • M May
  • JAC Sterne
  • M Shipley
  • E Brunner
  • R d'Agostino
  • P Whincup
  • Y Ben-Shlomo
  • A Carr
  • B Ledergerber
  • Jens Dilling Lundgren
  • AN Phillips
  • J Massaro
  • M Egger
View graph of relations

Background Many HIV-infected patients on highly active antiretroviral therapy (HAART) experience metabolic complications including dyslipidaemia and insulin resistance, which may increase their coronary heart disease (CHD) risk. We developed a prognostic model for CHD tailored to the changes in risk factors observed in patients starting HAART.

Methods Data from five cohort studies (British Regional Heart Study, Caerphilly and Speedwell Studies, Framingham Offspring Study, Whitehall II) on 13 100 men aged 40-70 and 114 443 years of follow up were used. CHD was defined as myocardial infarction or death from CHD. Model fit was assessed using the Akaike Information Criterion; generalizability across cohorts was examined using internal-external cross-validation.

Results A parametric model based on the Gompertz distribution generalized best. Variables included in the model were systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, triglyceride, glucose, diabetes mellitus, body mass index and smoking status. Compared with patients not on HAART, the estimated CHD hazard ratio (HR) for patients on HAART was 1.46 (95% CI 1.15-1.86) for moderate and 2.48 (95% CI 1.76-3.51) for severe metabolic complications.

Conclusions The change in the risk of CHD in HIV-infected men starting HAART can be estimated based on typical changes in risk factors, assuming that HRs estimated using data from non-infected men are applicable to HIV-infected men. Based on this model the risk of CHD is likely to increase, but increases may often be modest, and could be offset by lifestyle changes.

Original languageEnglish
JournalInternational Journal of Epidemiology
Volume36
Issue number6
Pages (from-to)1309-1318
Number of pages10
ISSN0300-5771
Publication statusPublished - 2007

    Research areas

  • Highly active antiretroviral therapy, protease inhibitors, non-nucleoside reverse transcriptase inhibitor, coronary heart disease, adverse effects, prognosis, coronary risk factors

ID: 32527696